Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 15-12G

REGENERON PHARMACEUTICALS INC Form 15-12G October 20, 2006 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-19034
REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
(914) 347-7000
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Preferred Share Purchase Rights (1)
(Title of each class of securities covered by this Form)
Common Stock par value \$.001 per share (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 15-12G Rule 12g-4(a)(2)(ii) [] Rule 12h-3(b)(2)(ii) [] Rule 15d-6 [] Approximate number of holders of record as of the certification or notice date: 0 (1) The Preferred Share Purchase Rights referred to herein expired on October 18, 2006, pursuant to the Rights Agreement, dated as of September 20, 1996, between Regeneron Pharmaceuticals, Inc. and Chase Mellon Shareholder Services LLC, as Rights Agent.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Regeneron Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: October 20, 2006 By: /s/ Stuart Kolinski

Stuart Kolinski

Vice President and General Counsel